No abstract

No abstract

BACKGROUND & AIMSDonation after circulatory death (DCD) in the UK has tripled in the last decade. However, outcomes following DCD liver transplantation are poorer than for brainstem death (DBD) liver transplants.This study examines whether a recipient to should accept a "poorer quality" DCD organ, or wait longer for a "better" DBD organ. METHODSSurvival following deceased donor liver transplantation performed between 2008 and 2015 was compared by Cox regression modelling to assess the impact on patient survival of accepting a DCD liver compared to deferring for a potential DBD transplant. RESULTS (23%) of the 3949 liver transplantations performed utilised DCD donors. Fiveyear transplant survival was poorer following DCD than DBD transplantation (69•1% (DCD) vs 78•3% (DBD); p <0•0001: adjusted hazard ratio [HR] = 1•65, 1•40 -1•94).Of the 5798 patients registered on the transplant list, 1325 (23%) died or were removed from the list without receiving a transplant. Patients who received DCD livers had a lower risk-adjusted hazard of death than those who remained on the waiting list for a potential DBD organ (adjusted HR 0•55, 0•47 -0•65). The greatest survival benefit was in those with the most advanced liver disease (adjusted HR 0•19 (0•07, 0•50). CONCLUSIONSAlthough DCD liver transplantation has poorer transplant outcomes, the individual's survival is enhanced by accepting a DCD offer particularly for patients with more severe liver disease. DCD liver transplantation improves overall survival for UK listed patients and should be encouraged.

Background There is renewed interest in the use of whole blood (WB) for the resuscitation of trauma patients. Platelet function in stored WB compared to platelet concentrates is not well established and was assessed in vitro in this study. Methods Leucocyte‐depleted cold‐stored WB (CS‐WB) was prepared using a Terumo WB‐SP Imuflex kit and held at 2–6°C alongside: (A) UK standard pooled platelets stored at 20–24°C (RT‐PLTS), (B) pooled platelets stored at 2–6°C (CS‐PLTS), and (C) platelet‐rich plasma produced using the Terumo kit (CS‐PRP), for 21 days. A series of in vitro assays were assessed platelet function. Results Platelet count was retained to 57 ± 14% of starting number at day 21 in CS‐WB. Over time, CS‐WB platelets become more activated, with increased CD62P expression (day 1: 7 ± 3.7% vs. day 21: 59 ± 17.1%) and annexin V binding (day 1: 2 ± 0.2% vs. day 21: 21 ± 15.1%). For comparison, 18.6 ± 6% of platelets in RT‐PLTS demonstrated CD62P expression at day 7, whereas annexin V binding in RT‐PLTS at day 7 was 2.6 ± 0.5%. Over storage, aggregatory response to agonists decreased in all arms. Functional platelet microparticles increased steadily in CS‐WB throughout storage. Conclusion During storage, platelet count reduced in CS‐WB, whereas CD62P expression and annexin V binding increased. This was accompanied by a reduced aggregatory response, although compared to 7‐day‐old RT‐PLTS, CS‐WB maintained a maximal response to agonists for longer, suggesting that the shelf life for CS‐WB can be considered for up to 21 days.

The data suggested that the pharmacokinetics of pranlukast are influenced by the time of dosing. Based on analysis of urinary 6 beta-hydroxycortisol excretion, there was no evidence that pranlukast modified the metabolic activity of cytochrome P-450 3A isoenzymes.